Pancreatic Cancer Research

ResearcherPeking UniversityActive in the last 2 years

Jun Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0570-1730; OpenAlex author ID A5034342116. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 7

  1. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. Co-author DOI 10.1200/jco.23.02314↗
  2. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. Co-author DOI 10.1186/s13045-023-01491-9↗
  3. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  4. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomi… Last author DOI 10.1007/s00432-020-03442-0↗
  5. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.12659/msm.927654↗
  6. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Co-author DOI 10.2147/ott.s168418↗
  7. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changsong Qi · 2 shared papers, 2023–2024 · strength 0.34
  2. Lin Shen · 2 shared papers, 2023–2024 · strength 0.34
  3. Guanghai Dai · 2 shared papers, 2020–2022 · strength 0.20
  4. Jun Zhang Zhang · 1 shared paper, 2024 · strength 0.17
  5. Yuan Zong · 1 shared paper, 2021 · strength 0.15
  6. Jian Wang · 2 shared papers, 2016–2022 · strength 0.13
  7. Yongwei Sun · 2 shared papers, 2016–2022 · strength 0.13
  8. Jihui Hao · 2 shared papers, 2016–2022 · strength 0.13
  9. Deliang Fu · 2 shared papers, 2016–2022 · strength 0.13
  10. Hanzhi Cui · 1 shared paper, 2020 · strength 0.11
  11. Wen Zhang · 1 shared paper, 2020 · strength 0.11
  12. Aiping Zhou · 1 shared paper, 2020 · strength 0.11
  13. Guochao Deng · 1 shared paper, 2020 · strength 0.11
  14. Changjie Lou · 1 shared paper, 2020 · strength 0.11
  15. Yanqiao Zhang · 1 shared paper, 2020 · strength 0.11
  16. Minyan Zeng · 1 shared paper, 2018 · strength 0.10
  17. Jin-Ling Tang · 1 shared paper, 2018 · strength 0.10
  18. Zu‐Yao Yang · 1 shared paper, 2018 · strength 0.10
  19. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  20. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  21. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  22. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  23. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  24. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  25. Chunyi Hao · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.